WO2016012913A1

WO2016012913A1 - Phenyl and tertbutylacetic acid substituted pyridinones having anti-hiv effects

Info

Publication number: WO2016012913A1
Application number: PCT/IB2015/055385
Authority: WO
Inventors: Brian Alvin Johns; Emile Johann Velthuisen
Original assignee: ViiV Healthcare UK Ltd
Current assignee: ViiV Healthcare UK Ltd
Priority date: 2014-07-21
Filing date: 2015-07-16
Publication date: 2016-01-28
Anticipated expiration: 2017-01-21
Also published as: AU2015293578A1; EP3172189A1; CN106536482A; MA40220A; US20170217890A1; TW201617317A; RU2016151973A3; IL249560A0; AR101222A1; ZA201608598B; JP2017521455A; RU2016151973A; UY36217A; CA2954724A1; KR20170032324A; CL2017000151A1; AU2015293578B2; US9802898B2

Abstract

Compounds of Formula I are disclosed and methods of treating viral invections with compositions comprising such compounds. Formula I

Description

PHENYL AND TERTBUTYLACETIC ACID SUBSTITUTED PYRIDINONES HAVING

ANTI-HIV EFFECTS

FIELD OF THE INVENTION

The present invention relates to substituted pyridone compounds, pharmaceutical compositions, and methods of use thereof for (i) inhibiting HIV replication in a subject infected with HIV, or (ii) treating a subject infected with HIV, by administering such compounds.

BACKGROUND OF THE INVENTION

Human immunodeficiency virus type 1 (HIV-1) leads to the contraction of acquired immune deficiency disease (AIDS). The number of cases of HIV continues to rise, and currently over twenty-five million individuals worldwide suffer from the virus. Presently, long-term suppression of viral replication with antiretroviral drugs is the only option for treating HIV-1 infection. Indeed, the U.S. Food and Drug Administration has approved twenty-five drugs over six different inhibitor classes, which have been shown to greatly increase patient survival and quality of life. However, additional therapies are still required because of undesirable drug-drug interactions; drug-food interactions; non-adherence to therapy; and drug resistance due to mutation of the enzyme target.

Currently, almost all HIV positive patients are treated with therapeutic regimens of antiretroviral drug combinations termed, highly active antiretroviral therapy ("HAART").

However, HAART therapies are often complex because a combination of different drugs must be administered often daily to the patient to avoid the rapid emergence of drug-resistant HIV-1 variants. Despite the positive impact of HAART on patient survival, drug resistance can still occur. The emergence of multidrug-resistant HIV-1 isolates has serious clinical consequences and must be suppressed with a new drug regimen, known as salvage therapy.

Current guidelines recommend that salvage therapy includes at least two, and preferably three, fully active drugs. Typically, first-line therapies combine three to four drugs targeting the viral enzymes reverse transcriptase and protease. One option for salvage therapy is to administer different combinations of drugs from the same mechanistic class that remain active against the resistant isolates. However, the options for this approach are often limited, as resistant mutations frequently confer broad cross-resistance to different drugs in the same class. Alternative therapeutic strategies have recently become available with the development of fusion, entry, and integrase inhibitors. However, resistance to all three new drug classes has already been reported both in the lab and in patients. Sustained successful treatment of HIV-1 - l infected patients with antiretroviral drugs will therefore require the continued development of new and improved drugs with new targets and mechanisms of action.

For example, over the last decade HIV inhibitors have been reported to target the protein-protein interaction between HIV-1 integrase and Lens Epithelium Derived Growth Factor/p75 ("LEDGF"). LEDGF is a cellular transcriptional cofactor of HIV-1 integrase that promotes viral integration of reverse transcribed viral cDNA into the host cell's genome by tethering the preintegration complex to the chromatin. Because of its crucial role in the early steps of HIV replication, the interaction between LEDGF and integrase represents another attractive target for HIV drug therapy.

SUMMARY OF THE INVENTION

Briefly, in one aspect, the present invention discloses compounds of Formula I:

Formula I

wherein:

R¹ is phenyl optionally substituted by one to four substituents selected from C_1-3alkyl, halogen, or -CH₂CH₂CH₂0- wherein this group is bonded to adjacent carbon atoms on the phenyl to form a ring;

L is a bond, d.₃alkylene, -S0₂-, -S0₂CH₂-, -NHS0₂-, -NHS0₂CH₂-, -C(O)-, -C(0)NH-, - C(0)NHCH₂-, -C(0)OCH₂-, -C(0)C(0)-, -CH₂C(0)-, C₃.₇heteroaryl, or -C₃.₇heteroarylNH-, wherein each heteroaryl comprises one to three heteroatoms selected from S, N, and O;

R² is H, cyclohexyl, or phenyl wherein said cyclohexyl and phenyl are optionally substituted by one to three substituents selected from C_1-3alkyl and halogen

R³ is H or -NHS0₂R⁴ wherein R⁴ is C_1-8alkyl and wherein said alkyl can include cycloalkyl portions.

In another aspect the present invention discloses pharmaceutically acceptable salts of the compounds of Formula I. In another aspect, the present invention discloses pharmaceutical compositions comprising a compound of Formula I or a pharmaceutically acceptable salt thereof.

In another aspect, the present invention discloses a method for treating a viral infection in a patient mediated at least in part by a virus in the retrovirus family of viruses, comprising administering to said patient a composition comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof. In some embodiments, the viral infection is mediated by the HIV virus.

In another aspect, a particular embodiment of the present invention provides a method of treating a subject infected with HIV comprising administering to the subject a therapeutically effective amount of a compound of Formula I, or a pharmaceutically acceptable salt thereof.

In yet another aspect, a particular embodiment of the present invention provides a method of inhibiting progression of HIV infection in a subject at risk for infection with HIV comprising administering to the subject a therapeutically effective amount of a compound of Formula I, or a pharmaceutically acceptable salt thereof. Those and other embodiments are further described in the text that follows.

In accordance with another embodiment of the present invention, there is provided a method for preventing or treating a viral infection in a mammal mediated at least in part by a virus in the retrovirus family of viruses which method comprises administering to a mammal, that has been diagnosed with said viral infection or is at risk of developing said viral infection, a compound as defined in Formula Iwherein said virus is an HIV virus and further comprising administration of a therapeutically effective amount of one or more agents active against an HIV virus, wherein said agent active against the HIV virus is selected from the group consisting of Nucleotide reverse transcriptase inhibitors; Non-nucleotide reverse transcriptase inhibitors; Protease inhibitors; Entry, attachment and fusion inhibitors; Integrase inhibitors; Maturation inhibitors; CXCR4 inhibitors; and CCR5 inhibitors.

DETAILED DESCRIPTION OF THE INVENTION

Preferably R¹ is phenyl optionally substituted by a methyl group.

Preferably L is a bond, -oxadiazolyl-NH-, -C(0)NH-, or -C(0)NHCH₂-.

Preferably R² is H, cyclohexyl, or phenyl wherein said cyclohexyl and phenyl are optionally substituted by 1 or 2 methyl groups.

Preferably R³ is H, -NHS0₂CH₃, or -NHS0₂CH₂cyclohexyl. Preferably the stereochemistry on the carbon to which the t-butyl group is bound is as depicted below.

"Pharmaceutically acceptable salt" refers to pharmaceutically acceptable salts derived from a variety of organic and inorganic counter ions well known in the art and include, by way of example only, sodium, potassium, calcium, magnesium, ammonium, and tetraalkylammonium, and when the molecule contains a basic functionality, salts of organic or inorganic acids, such as hydrochloride, hydrobromide, tartrate, mesylate, acetate, maleate, and oxalate. Suitable salts include those described in P. Heinrich Stahl, Camille G. Wermuth (Eds.), Handbook of Pharmaceutical Salts Properties, Selection, and Use; 2002.

Examples

The compounds of this invention may be made by a variety of methods, including well- known standard synthetic methods. Illustrative general synthetic methods are set out below and then specific compounds of the invention are prepared in the working examples.

Scheme 1

Example 1 : 4A-Di ethyl-2-(5-methyl-4-(((1rAr)-4-methylcvclohexyl)carbamoyl)-2-oxo-6-(D- tolvDDyridin- 1 (2H)-yl)pentanoic acid

Step 1 : (E)-Ethyl 2-(4-hydroxybut-2-enamido)-4A-dimethylDentanoate

To a solution of (E)-4-hydroxybut-2-enoic acid (418 mg, 4.09 mmol) in DMF (5 mL) were added DIPEA (3.5 mL, 20.5 mmol), HBTU (3.2 g, 8.2 mmol) and ethyl 2-amino-4,4- dimethylpentanoate (1 .05 g, 6.1 mmol). After 30 min, the reaction mixture was partitioned between DCM and water. The layers were separated and the aqueous layer was extracted with DCM (20 mL X 2). The combined organic layers was washed with NaHC0₃ (aq.) and brine, dried over Na₂S0₄, filtered and concentrated under reduced pressure to give the crude product which was purified by column chromatography (silica gel, PE:EA = 1 : 1) to afford the title compound as a yellow solid (1 .05 g, 64% yield). LC-MS (ESI): m/z (M+1 ) = 258.23.

Step 2: (E)-ethyl 2-(4-(tert-butyldimethylsilyloxy)but-2-enamido)AA-dimethylDentanoate

To a solution of (E)-ethyl 2-(4-hydroxybut-2-enamido)-4,4-dimethylpentanoate (1 .05 g, 4.1 mmol) in DCM (10 mL) were added DMAP (498 mg, 4.1 mmol), imidazole (833 mg, 12.3 mmol) and TBSCI (922 mg, 6.2 mmol). After 2 h, the reaction mixture was quenched with H₂0 and extracted with DCM (20 ml X 3). The combined organic layers were washed with brine, dried over Na₂S0₄, filtered and concentrated under reduced pressure to give the crude product which was purified by column chromatography (silica gel, PE:EA = 5: 1) to afford the title compound as a yellow oil (800 mg, 53% yield). LC-MS (ESI): m/z (M+1 ) = 372.24.

Step 3: Ethyl 2-(4-((tert-butyldimethylsilyloxy)methyl)-5-methyl-2-oxo-6-p-tolylpy^ 1 (2H)-yl)-

4,4-dimethylpentanoate

1-Methyl-4-(prop-1-yn-1-yl)benzene was prepared from the known procedure as described in Angew. Chem. Int. Edit, 2012 51 , 1287-1294.

A mixture of (E)-ethyl 2-(4-(tert-butyl dimethylsilyloxy)but-2-enamido)-4,4-adimethyl pentanoate (300 mg, 0.81 mmol), 1 -methyl-4-(prop-1-ynyl)benzene (132 mg, 1 .0 mmol), RhCp^*(MeCN)₃(SbF₆)₂ (33.7 mg, 0.04 mmol) and Cu(OAc)₂ H₂0 (340 mg, 1 .7 mmol) in DCE (10 mL) was stirred at 80°. After 18h, the mixture was cooled down to ambient temperature and quenched with 10% NH₃ H₂0 in saturated NH₄CI (aq.) and extracted with DCM (20 mL x 3). The combined organic layers was washed with brine, dried over Na₂S0₄, filtered and concentrated under reduced pressure to give the crude product which was purified by column

chromatography (silica gel, 2% MeOH in DCM) to afford the title compound as a yellow solid (1 14 mg, 28% yield). LC-MS (ESI): m/z (M+1 ) = 500.31

Step 4: Ethyl 2-(4-(hvdroxymethyl)-5-methyl-2-oxo-6-D-tolylDyridin-1 (2H)-yl)-4A- dimeth ylpentanoate

To a solution of ethyl 2-(4-((tert-butyldimethylsilyloxy)methyl)-5-methyl-2-oxo-6-p-tolyl pyridin-1 (2H)-yl)-4,4-dimethylpentanoate (1 14 mg, 0.23 mmol) in THF (3 mL) was added TBAF (120 mg, 0.46 mmol). After 1 h, the reaction mixture was partitioned between EtOAc and water. The layers were separated and the organic layer was washed with H20 and brine, dried over Na2S04, filtered and concentrated under reduced pressure to give the title compound as a yellow oil (108 mg, quant, yield) which was used in next step without further purification. LC-MS (ESI): m/z (M+1 ) 386.18.

A solution of ethyl 2-(4-(hydroxymethyl)-5-methyl-2-oxo-6-p-tolylpyridin-1 (2/-/) -yl)-4,4- dimethylpentanoate (108 mg ,0.28 mmol) in DCM (5 mL) was added DMP (214 mg , 0.50 mmol). After 1 h, the reaction mixture was quenched with NaHC0₃ (aq.) and extracted with DCM (20 ml X 3). The combined organic layers was washed with brine, dried over Na₂S0₄, filtered and concentrated under reduced pressure to give the crude product which was purified by column chromatography (silica gel, PE:EA = 2:1 ) to afford the title compound as a yellow solid (63 mg, 58% yield). LC-MS (ESI): m/z (M+1 ) = 384.3.

Step 6: 1 -(1 -Ethoxy-4A-dimethyl-1 -oxoDentan-2-yl)-5-methyl-2-oxo-6-D-tolyl-1 ,2- dih ydrop yridine-4-carboxylic acid

To a solution of ethyl 2-(4-formyl-5-methyl-2-oxo-6-p-tolylpyridin-1 (2/-/)-yl)-4,4- dimethylpentanoate (63 mg, 0.16 mmol) in THF (2.2 mL), f-BuOH (2.2 mL) and isobutylene (4.5 ml) in a sealed tube was added a solution of NaH₂P0₄ and NaCI0₂ in H₂0 (5 mL). After 18h, the reaction mixture was acidified with 1 N HCI (0.5 mL) and extracted with ethyl acetate (20 ml X 3). The combined organic layers was washed with brine, dried over Na₂S0₄, filtered and

concentrated under reduced pressure to give the title compound as a yellow solid (51 mg, 80% yield) which was used in next step without further purification. LC-MS (ESI): m/z (M+1 ) = 400.1

Step 7: Ethyl 4,4-dimethyl-2-(5-methyl-4-((1r,4r)-4-methylcyclohexylcarba moyl)-2-oxo-6-D- tolylpyridin- 1 (2H)-yl)pentanoate

A solution of 1 -(1 -ethoxy-4,4-dimethyl-1 -oxopentan-2-yl)-5-methyl-2-oxo-6-p-tolyl- 1 ,2- dihydropyridine-4-carboxylic acid (28 mg, 0.07 mmol) in DMF (2 mL) was treated with DIPEA (0.06 ml , 0.35 mmol), HBTU (54.2 mg, 0.14 mmol) and irans-4-methyl cyclohexyl amine (0.02 ml, 0.14 mmol). After 18h, the reaction mixture was diluted with water and extracted with DCM (20 ml X 3). The combined organic layers was washed with NaHC0₃ (aq.) and brine, dried over Na₂S0₄, filtered and concentrated under reduced pressure to give the crude product which was purified by prep. TLC (PE:EA = 1 :1 ) to afford the title compound as a yellow solid (30 mg, 86%). LC-MS (ESI): m/z (M+1 ) = 495.37.

Step 8: 4A-Dimethyl-2-(5-methyl-4-((1rAr)-4-methylcvclohexylcarbamoyl)-2-oxo-6-D-tolylDv

1 (2H)-yl)pentanoic acid

To a solution of ethyl 4,4-dimethyl-2-(5-methyl-4-((1 r,4r)-4-methylcyclohexylcarbamo yl)- 2-oxo-6-p-tolylpyridin-1 (2H)-yl)pentanoate (30 mg, 0.06 mmol) in MeOH (2 mL) was added 1 N NaOH (0.6 mL) and heated to reflux. After 18h, the reaction mixture was cooled to ambient temperature, acidified with 1 N HCI (0.6 mL) (pH = 6~7) and concentrated under reduced pressure to give the crude product which was purified by reverse phase HPLC (C₁₈ 70~100% CH₃CN in H₂0 with 0.1 % formic acid) to afford the title compound as a white powder (12 mg, 40% yield). ¹H NMR (400 MHz, DMSO) δ 8.43 (d, J = 8.0 Hz, 1 H), 7.46 - 7.31 (m, 3H), 7.28 (d, J = 8.1 Hz, 1 H), 6.24 (s, 1 H), 4.19 (s, 1 H), 3.63 - 3.58 (m, 1 H), 2.39 (s, 3H), 2.31 - 2.23 (m, 1 H), 1 .92 - 1.77 (m, 3H), 1 .76 - 1 .60 (m, 5H), 1 .32 - 1 .23 (m, 3H), 1 .05 - 0.95 (m, 2H), 0.87 (d, J = 6.5 Hz, 3H), 0.58 (s, 9H). LC-MS (ESI): m/z (M+1 ) = 467.33.

Scheme 2

Example 2 : 2-(4-(3A-DimethylDhenyl)-5-methyl-2-oxo-6-(D-tolyl)Dyridin- 1 (2H)-yl)-4A- dimethylpentanoic acid

Step 1 : (E)-Ethyl 2-(3-(3A-dimethylDhenyl)acrylamido)-4,4-dimethylDentanoate.

A mixture of (E)-3-(3,4-dimethylphenyl)acrylic acid (200 mg, 1 .14 mmol), ethyl 2-amino- 4,4-dimethylpentanoate (240 mg, 1.4 mmol), HBTU (880 mg, 2.3 mmol) and DIPEA (733 mg, 5.7 mmol) in DCM (10 mL) was stirred at r.t. for 40min. The reaction mixture was diluted with sat. NaHC0₃ (aq.) and extracted with DCM (20 ml X 3). The combined organic layers were washed with brine, dried over Na₂S0₄, filtered and concentrated under reduced pressure to give the crude product which was purified by column chromatography (silica gel, PE:EA = 3:1 ) to afford the title compound as a yellow oil (288 mg, 77% yield). LC-MS (ESI): m/z (M+1 ) = 332.3.

Step 2: Ethyl 2-(4-(3A-dimethylDhenyl)-5-methyl-2-oxo-6-(D-tolyl)Dyrid^

dimeth ylpentanoate

A mixture of (E)-Ethyl 2-(3-(3,4-dimethylphenyl)acrylamido)-4,4-dimethylpentanoate (60 mg, 0.18 mmol), 1-methyl-4-(prop-1-ynyl)benzene (24 mg, 0.18 mmol), RhCp^*(MeCN)₃(SbF₆)₂ (7.5 mg, 0.01 mmol) and Cu(OAc)₂ H₂0 (152 mg, 0.76 mmol) in DCE (2 mL) was stirred at 100°C. After 24h, the mixture was cooled down to ambient temperature and quenched with 10% ΝΗ₃Ή₂Ο in saturated NH₄CI (aq.) and extracted with DCM (10 ml_ x 3). The combined organic layers was washed with brine, dried over Na₂S0₄, filtered and concentrated under reduced pressure to give the crude product which was purified by column chromatography (silica gel, PE:EA = 3: 1 ) to afford the title compound as a yellow oil (50 mg, 60% yield). LC-MS (ESI): m/z (M+1) = 460.5.

Step 3: 2-(4-(3A-dimethylDhenyl)-5-methyl-2-oxo-6-(D-tolyl)Dyridin- 1 (2H)-yl)-4,4- dimethylpentanoic acid

To a solution of Ethyl 2-(4-(3,4-dimethylphenyl)-5-methyl-2-oxo-6-(p-tolyl)pyridin-1 (2/-/)- yl)-4,4-dimethylpentanoate (50 mg, 0.1 1 mmol) in MeOH (2 mL) was added 1 N NaOH (1.0 mL) and heated to reflux. After 12h, the reaction mixture was cooled to ambient temperature, acidified with 1 N HCI (1 .0 mL) (pH = 6~7) and concentrated under reduced pressure to give the crude product which was purified by reverse phase HPLC (C₁₈ 50~100% CH₃CN in H₂0 with 0.1 % formic acid) to afford the title compound as a white powder (37 mg, 77% yield). ¹H NMR (400 MHz, DMSO) δ 12.86 (br, 1 H), 7.57 - 6.99 (m, 7H), 6.24 (s, 1 H), 4.27 (s, 1 H), 2.39 (s, 3H), 2.36 - 2.15 (m, 7H), 1 .96 - 1.79 (m, 1 H), 1 .58 (s, 3H), 0.61 (s, 9H). LC-MS (ESI): m/z (M+1 ) = 432.4.

Scheme 3

Example 3: 2-(4-(3A-dimethylDhenyl)-5-methyl-3-(methylsulfonamido)-2-oxo

1 (2H)-yl)-4,4-dimethylDentanoic acid

Step 1 : Ethyl 2-(4-(3A-dimethylDhenyl)-5-methyl-3-nitro-2-oxo-6-(D-toM^

dimeth ylpentanoate

To a mixture of Ethyl 2-(4-(3,4-dimethylphenyl)-5-methyl-2-oxo-6-p-tolylpyridin-1 (2/-/)-yl)- 4,4-dimethylpentanoate (153 mg, 0.33 mmol) and NaN0₂ (28 mg, 0.37 mmol) in DCM (5 mL) was added TFA (0.5 mL) under 0₂ atmosphere. After 12h, the reaction mixture was quenched with sat. NaHC0₃ (aq.) and extracted with DCM (20 ml X 3). The combined organic layers were washed with brine, dried over Na₂S0₄, filtered and concentrated under reduced pressure to give the crude product which was purified by column chromatography (silica gel, PE:EA = 3:1 ) to afford the title compound as a yellow oil (140 mg, 83% yield). LC-MS (ESI): m/z (M+1 ) = 505.3.

Step 2: Ethyl 2-(3-amino-4-(3A-dimethylDhenyl)-5-methyl-2-oxo-6-(D-tolyl)DyridM

dimeth ylpentanoate

A mixture of Ethyl 2-(4-(3,4-dimethylphenyl)-5-methyl-3-nitro-2-oxo-6-p-tolylpyridin- 1 (2H)-yl)-4,4-dimethylpentanoate (140 mg, 0.28 mmol) and Pd/C (130 mg) in EtOAc (5 mL) was purged with H₂ three times. After 2h, the reaction mixture was filtered through Celite pad and the filtrate was concentrated under reduced pressure to afford the title compound as a yellow solid (133 mg, 99% yield). LC-MS (ESI): m/z (M+1 ) = 475.4.

Step 3: Ethyl 2-(4-(3A-dimethylDhenyl)-5-methyl-3-(methylsulfonamido)-2-oxo-6-(D-tolyl)Dv

1 (2H) - yl) -4A-dimeth ylpentanoate

To a solution of Ethyl 2-(4-(3,4-dimethylphenyl)-5-methyl-3-(methylsulfonamido)-2-oxo-6- (p-tolyl)pyridin-1 (2H)-yl)-4,4-dimethylpentanoate (36 mg, 0.076 mmol) and DMAP (5 mg, 0.003 mmol) in pyridine (1 mL) was added MsCI (44 mg, 0.38 mmol). After 12h, the reaction mixture was diluted with sat. NH₄CI (aq.) and extracted with EtOAc (10 ml X 3). The combined organic layers were washed with brine, dried over Na₂S0₄, filtered and concentrated under reduced pressure to give the crude product which was purified by column chromatography (silica gel, PE:EA = 2: 1 ) to afford the title compound as a yellow oil (24 mg, 57% yield). LC-MS (ESI): m/z (M+1) = 553.4.

Step 4: 2-(4-(3A-DimethylDhenyl)-5-methyl-3-(methylsulfonamido)-2-oxo-6-(D-toM

1 (2H)-yl)-4A-dimethylpentanoic acid

To a solution of Ethyl 2-(4-(3,4-dimethylphenyl)-5-methyl-3-(methylsulfonamido)-2-oxo-6- (p-tolyl)pyridin-l (2 - )-yl)-4,4-dimethylpentanoate (30 mg, 0.054 mmol) in MeOH (2 mL) was added 1 N NaOH (0.6 mL) and heated to reflux. After 12h, the reaction mixture was cooled to ambient temperature, acidified with 1 N HCI (0.6 mL) (pH = 6~7) and concentrated under reduced pressure to give the crude product which was purified by reverse phase HPLC (C₁₈ 60~100% CH₃CN in H₂0 with 0.1 % formic acid) to afford the title compound as a white powder (14 mg, 49% yield). ¹ H NMR (400 MHz, DMSO) δ 12.93 (br, 1 H), 8.30 (s, 1 H), 7.51 - 7.27 (m, 4H), 7.28 - 7.16 (m, H), 7.08 - 6.92 (m, 2H), 4.31 (s, 1 H), 2.91 (d, = 4.6Hz, 3H), 2.41 - 2.31 (m, 4H), 2.31 - 2.18 (m, 6H), 1 .94 - 1 .86 (m, 1 H), 1 .41 (s, 3H), 0.61 (s, 9H). LC-MS (ESI): m/z (M+1) = 525.8.

Example 4: 4A-Dimethyl-2-(5-methyl-3-(methylsulfonamido)-2-oxo-6-(D-tolyl)Dyridi vDoentanoic acid

Step 1 : Ethyl 2-acrylamido-4A-dimethylDentanoate

To a solution of Ethyl 2-amino-4,4-dimethylpentanoate (150 mg, 0.86 mmol) in DCM (4 mL) was added acryloyi chloride (156 mg, 1.72 mmol). After 1 h, the reaction mixture was diluted with sat. NaHC0₃ (aq.) and extracted with DCM (20 ml X 2). The combined organic layers were washed with brine, dried over Na₂S0₄, filtered and concentrated under reduced pressure to give the crude product which was purified by column chromatography (silica gel, DCM:MeOH = 20:1 ) to afford the title compound as a yellow solid (190 mg, 96% yield). LC-MS (ESI): m/z (M+1 ) = 228.3.

Step 2: Ethyl 4A-dimethyl-2-(5-methyl- -oxo-6-(D-tolyl)Dyridin-1(2H)-yl)Dentanoate

A mixture of Ethyl 2-acrylamido-4,4-dimethylpentanoate (200 mg, 0.18 mmol), 1 -methyl- 4-(prop-1 -ynyl)benzene (250 mg, 0.35 mmol), RhCp^*(MeCN)₃(SbF₆)₂ (30 mg, 0.01 mmol) and Cu(OAc)₂ H₂0 (365 mg, 0.37 mmol) in DCE (4 mL) was stirred at 100°C. After 24h, the mixture was cooled down to ambient temperature and quenched with 10% NH₃ H₂0 in saturated NH₄CI (aq.) and extracted with DCM (10 mL x 3). The combined organic layers was washed with brine, dried over Na₂S0₄, filtered and concentrated under reduced pressure to give the crude product which was purified by column chromatography (silica gel, PE:EA = 2:1 ) to afford the title compound as a yellow oil (50 mg, 16% yield). LC-MS (ESI): m/z (M+1 ) = 356.2.

Step 3: Ethyl 2-(3-bromo-5-methyl-2-oxo-6-(D-tolyl)Dvndin-1(2 )-yl)-4A-dimethylDentanoate

To a solution of Ethyl 4,4-dimethyl-2-(5-methyl-2-oxo-6-(p-tolyl)pyridin-1 (2/-/)- yl)pentanoate (105 mg, 0.3 mmol) in CHCI₃ (4 mL) was added NBS (61 mg, 0.33 mmol) and heated to 40°C. After 12h, the reaction mixture was diluted with water and extracted with DCM (20 ml X 2). The combined organic layers were washed with brine, dried over Na₂S0₄, filtered and concentrated under reduced pressure to give the crude product which was purified by column chromatography (silica gel, PE:EA = 5: 1) to afford the title compound as a yellow oil (1 15 mg, 90% yield). LC-MS (ESI): m/z (M/M+2) = 434.2/436.2.

Step 4: Ethyl 2-(3-((diDhenylmethylene)amino)-5-methyl-2-oxo-6-(D-tolyl)Dyridi

dimeth ylpentanoate

A mixture of Ethyl 2-(3-bromo-5-methyl-2-oxo-6-(p-tolyl)pyridin-1 (2H)-yl)-4,4- dimethylpentanoate (130 mg, 0.30 mmol), diphenylmethanimine (165 mg, 0.90 mmol), Pd₂(dba)₃ (30 mg, 0.03 mmol), Xantphos (17 mg, 0.03 mmol) and Cs₂C0₃ (292 mg, 0.90 mmol) in dioxane (3 mL) was stirred at 90°C under N₂ atmosphere. After 20h, the mixture was cooled down to ambient temperature, diluted with water and extracted with EtOAc (20 mL x 3). The combined organic layers was washed with brine, dried over Na₂S0₄, filtered and concentrated under reduced pressure to give the crude product which was purified by column chromatography (silica gel, PE:EA = 3:1 ) to afford the title compound as a yellow oil (100 mg, 63% yield). LC-MS (ESI): m/z (M+1 ) = 535.3.

Step 5: Ethyl 2-(3-amino-5-methyl-2-ox -6-(D-tolyl)Dvndin-1(2 )-yl)-4A-dimethylDentano

To a solution of Ethyl 2-(3-((diphenylmethylene)amino)-5-methyl-2-oxo-6-(p-tolyl)pyridin- 1 (2H)-yl)-4,4-dimethylpentanoate (100 mg, 0.19 mmol) in MeOH (5 mL) was added 1 N HCI (1 mL). After 1 h, the reaction mixture was neutralized with sat. NaHC0₃ (aq.) and extracted with DCM (20 ml X 2). The combined organic layers were washed with brine, dried over Na₂S0₄, filtered and concentrated under reduced pressure to give the crude product which was purified by column chromatography (silica gel, PE:EA = 2:1 ) to afford the title compound as a yellow oil (53 mg, 77% yield). ¹ H NMR (400 MHz, DMSO) δ 7.31 (t, J = 6.9 Hz, 2H), 7.23 (dd, J = 8.7, 7.1 Hz, 2H), 6.40 (s, 1 H), 5.13 (s, 2H), 4.32 (s, 1 H), 4.22 - 4.1 1 (m, 1 H), 4.10 - 3.95 (m, 2H), 2.36 (s, 3H), 2.28 - 2.19 (m, 1 H), 1 .89 - 1 .79 (m, 1 H), 1.74 (s, 3H), 1 .17 (q, J = 7.1 Hz, 3H), 0.56 (s, 9H). LC-MS (ESI): m/z (M+1) = 371.2.

Step 6: Ethyl 4A-dimethyl-2-(5-methyl-3-(methylsulfonamido)-2-oxo-6^ 1 (2H)- vDoentanoate

To a solution of Ethyl 2-(3-amino-5-methyl-2-oxo-6-(p-tolyl)pyridin-1 (2/-/)-yl)-4,4- dimethylpenta noate (13 mg, 0.035 mmol) and DMAP (1 mg, 0.008 mmol) in pyridine (2 mL) was added MsCI (12 mg, 0.105 mmol). After 1 h, the reaction mixture was quenched with sat. NH₄CI (aq.) and extracted with DCM (20 ml X 2). The combined organic layers were washed with brine, dried over Na₂S0₄, filtered and concentrated under reduced pressure to afford the title compound as a yellow oil (53 mg, 77% yield) which was used in next step without further purification. LC-MS (ESI): m/z (M+1 ) = 449.3.

Step 7: 4A-Dimethyl-2-(5-methyl-3-(methylsulfonamido)-2-oxo^ 1 (2H)- vDoentanoic acid

To a solution of Ethyl 4,4-dimethyl-2-(5-methyl-3-(methylsulfonamido)-2-oxo-6-(p- tolyl)pyridin-1 (2H)-yl)pentanoate (15 mg, 0.033 mmol) in MeOH (3 mL) was added 1 N NaOH (0.3 mL) and heated to reflux. After 6h, the reaction mixture was cooled to ambient temperature, acidified with 1 N HCI (0.3 mL) (pH = 6~7) and concentrated under reduced pressure to give the crude product which was purified by reverse phase HPLC (C₁₈ 60~100% CH₃CN in H₂0 with 0.1 % formic acid) to afford the title compound as a white powder (7 mg, 50% yield). ¹ H NMR (400 MHz, DMSO) δ 12.93 (br, 1 H), 8.88 (s, 1 H), 7.45 - 7.22 (m, 5H), 4.34 (s, 1 H), 3.09 (s, 3H), 2.39 (s, 3H), 2.23 (dd, J = 15.1 , 3.7 Hz,1 H), 1.98 - 1 .91 (m, 1 H), 1 .81 (s, 3H), 0.57 (s, 9H). LC- MS (ESI): m/z (M+1 ) = 421 .2.

Scheme 5

Example 5: 4,4-dimethyl-2-(5-methyl-4-(((1 s^s^'l^-methylcyclohexyncarbamovn-S- (methylsulfonamido^')-2-oxo-6-(p-tolyl^') ^')-yl^')pentanoic acid

Step 1 : Ethyl 2-(4-(((tert-butyldimethylsilyl)oxy)methyl)-5-methyl-3-nitro-2-oxo-6-(D-toM

1 (2H) - yl) -4,4-dimeth ylpentanoate

To a mixture of Ethyl 2-(4-((tert-butyldimethylsilyloxy)methyl)-5-methyl-2-oxo-6-p- tolylpyridin-1 (2/-/)-yl)-4,4-dimethylpentanoate (50 mg, 0.10 mmol), NaN0₂ (7.5 mg, 0.1 1 mmol) in DCM (5 mL) was added TFA (0.05 mL) under 0₂ atmosphere. After 12h, the reaction mixture was quenched with sat. NaHC0₃ (aq.) and extracted with DCM (20 ml X 3). The combined organic layers were washed with brine, dried over Na₂S0₄, filtered and concentrated under reduced pressure to give the crude product which was purified by column chromatography (silica gel, PE:EA = 5: 1 ) to afford the title compound as a yellow oil (54 mg, 92% yield). LC-MS (ESI): m/z (M+1 ) = 545.6.

Step 2: Ethyl 2-(4-(hydroxymethyl)-5-methyl-3-nitro-2-oxo-6-(D-tolyl)Dyridin-1(2H^

dimeth ylpentanoate

To a solution of Ethyl 2-(4-(((tert-butyldimethylsilyl)oxy)methyl)-5-methyl-3-nitro-2-oxo-6- (p-tolyl)pyridin-1 (2/-/)-yl)-4,4-dimethylpentanoate (138 mg, 0.25 mmol) in THF (10 mL) was added TBAF (133 mg, 0.51 mmol). After 30min, the reaction mixture was partitioned between EtOAc and water. The layers were separated and the organic layer was washed with H₂0 and brine, dried over Na₂S0₄, filtered and concentrated under reduced pressure to give the crude product which was purified by column chromatography (silica gel, PE:EA = 2:1 ) to afford the title compound as a yellow oil (104 mg, 95% yield). LC-MS (ESI): m/z (M+1 ) 431 .4.

Step 3: Ethyl 2-(4-formyl-5-methyl-3-nitro-2-oxo-6-(D-tolyl)DyridM

dimeth ylpentanoate

To a solution of Ethyl 2-(4-(hydroxymethyl)-5-methyl-3-nitro-2-oxo-6-(p-tolyl)pyridin- 1 (2H)-yl)-4,4-dimethylpentanoate (33 mg ,0.08 mmol) in DCM (5 mL) was added DMP (49 mg , 0.12 mmol). After 1 h, the reaction mixture was quenched with NaHC0₃ (aq.) and extracted with DCM (20 ml X 3). The combined organic layers was washed with brine, dried over Na₂S0₄, filtered and concentrated under reduced pressure to give the crude product which was purified by column chromatography (silica gel, DCM) to afford the title compound as a yellow solid (27 mg, 82% yield). LC-MS (ESI): m/z (M+1 ) = 429.5. Step 4: 1 -(1 -Ethoxy-4A-dimethyl-1 -oxoDentan-2-yl)-5-methyl-3-nitro-2-oxo-6-(D-tolyl)-1 ,2- dih vdroD yridine-4-carboxylic acid

To a solution of Ethyl 2-(4-formyl-5-methyl-3-nitro-2-oxo-6-(p-tolyl)pyridin-1 (2/-/)-yl)-4,4- dimethyl pentanoate (27 mg, 0.06 mmol) in THF (1 mL), M3uOH (1 mL) and isobutylene (1 ml) in a sealed tube was added a solution of NaH₂P0₄ (59 mg, 0.38 mmol) and NaCI0₂ (46 mg, 0.50 mmol) in H₂0 (1 mL). After 12h, the reaction mixture was acidified with 1 N HCI and extracted with EtOAc (20 ml X 3). The combined organic layers was washed with brine, dried over Na₂S0₄, filtered and concentrated under reduced pressure to give the title compound as a yellow solid (30 mg, 99% yield) which was used in next step without further purification. LC-MS (ESI): m/z (M+1 ) = 445.5

Step 6: Ethyl 4,4-dimethyl-2-(5-methyl-4-((( 1sAs)-4-methylcvclohexyl)carbamoyl)-3-nitro-2-oxo-

6-(D-tolyl)Dyridin- 1 (2H)-yl)pentanoate

A solution of 1 -(1 -ethoxy-4,4-dimethyl-1 -oxopentan-2-yl)-5-methyl-3-nitro-2-oxo-6-(p- tolyl)-1 ,2-dihydropyridine-4-carboxylic acid (30 mg, 0.067 mmol) in DMF (3 mL) was treated with DIPEA (35 mg, 0.27 mmol), HBTU (52 mg, 0.13 mmol) and irans-4-methyl cyclohexyl amine (15 mg, 0.14 mmol). After 30min, the reaction mixture was diluted with water and extracted with EtOAc (20 ml X 3). The combined organic layers was washed with brine, dried over Na₂S0₄, filtered and concentrated under reduced pressure to give the crude product which was purified by column chromatography (silica gel, PE:EA = 2:1 ) to afford the title compound as a yellow oil (18 mg, 50%). LC-MS (ESI): m/z (M+1 ) = 540.8. Step 7: Ethyl 2-(3-amino-5-methyl-4-((( 1s,4s)-4-methylcyclohexyl)carbamoyl)-2-oxo-6-(D- tolyl)pyridin- 1 i2H)-yl)-4,4-dimethylpentanoate

A mixture of Ethyl 4,4-dimethyl-2-(5-methyl-4-(((1 s,4s)-4-methylcyclohexyl)carbamoyl)-3- nitro-2-oxo-6-(p-tolyl)pyridin-1 (2/-/)-yl)pentanoate (18 mg, 0.03 mmol) and Pd/C (10 mg) in EtOAc (5 mL) was purged with H₂ three times. After 12h, the reaction mixture was filtered through Celite pad and the filtrate was concentrated under reduced pressure to afford the title compound as a yellow solid (10 mg, 65% yield). LC-MS (ESI): m/z (M+1) = 510.6.

Step 8: Ethyl 4,4-dimethyi-2-(5-methyi-4-(((1s,4s)-4-methyicyciohexyi)carbamoyi)-3- (methylsulfonamido)-2-oxo-6-iD-tolyl)Dyridin-1{2H)-yl)Dentanoate

To a solution of Ethyl 2-(3-amino-5-methyl-4-(((1 s,4s)-4-methylcyclohexyl)carbamoyl)-2- oxo-6-(p-tolyl)pyridin-1 (2H)-yl)-4,4-dimethylpentanoate (19 mg, 0.037 mmol) and DMAP (1 mg, 0.008 mmol) in pyridine (2 mL) was added MsCI (0.03 mL, 0.37 mmol). After 2h, the reaction mixture was diluted with water and extracted with EtOAc (20 ml X 2). The combined organic layers were washed with brine, dried over Na₂S0₄, filtered and concentrated under reduced pressure to give the crude product which was purified by column chromatography (silica gel, PE:EA = 2: 1 ) to afford the title compound as a yellow oil (5 mg, 23% yield). LC-MS (ESI): m/z (M+1) = 588.7.

Step 9: 4,4-Dimethyl-2-(5-methyl-4-((( 1s ,4s) -4-methylcyclohexyl) carbamoyl) -3- (methylsulfonamido)-2-oxo-6-(D-tolyl)Dyridin- 1 (2H)-yl)pentanoic acid

To a solution of Ethyl 4,4-dimethyl-2-(5-methyl-4-(((1s,4s)-4- methylcyclohexyl)carbamoyl)-3-(methylsulfonamido)-2-oxo-6-(p-tolyl)pyridin-1(2/-/)- yl)pentanoate (5 mg, 0.008 mmol) in MeOH (2 mL) was added 1 N NaOH (0.2 mL) and heated to reflux. After 12h, the reaction mixture was cooled to ambient temperature, acidified with 1 N HCI (0.2 mL) (pH = 6~7) and concentrated under reduced pressure to give the crude product which was purified by reverse phase HPLC (C₁₈10~100% CH₃CN in H₂0 with 0.1% formic acid) to afford the title compound as a white powder (3 mg, 67% yield).¹H NMR (400 MHz, DMSO) δ 8.33 (s, 1H), 7.87 (d, J= 7.2 Hz, 1H), 7.48-7.34 (m, 3H), 7.26 (d, J= 7.6 Hz, 1H), 4.19 (s, 1H), 3.65-3.61 (m, 1H), 3.14 (s, 3H), 2.39 (s, 3H), 2.31 -2.26 (m, 1H), 1.93- 1.80 (m, 3H), 1.75- 1.56 (m, 5H), 1.32- 1.20 (m, 3H), 1.03-0.94 (m, 2H), 0.87 (d, J=6A Hz, 3H), 0.57 (s, 9H). LC-MS (ESI): m/z (M+1) = 560.6.

Example 6: 4A-Di ethyl-2-(5-methyl-4-(5-(((1r,4r)-4-methylcvclohexyl)amino)-1 ,3,4-oxadiazol- 2-yl)-2-oxo-6-(D-tolyl)Dyridin- 1 (2H)-yl)pentanoic acid

Step 1 : Ethyl 2-(4-(hydrazinecarbonyl)-5-methyl-2-oxo-6-(p-tolyl)pyridM

di^'meth ylpentanoate

To a solution of 1 -(1-ethoxy-4,4-dimethyl-1 -oxopentan-2-yl)-5-methyl-2-oxo-6-p-tolyl-1 ,2- dihydropyridine-4-carboxylic acid (66 mg, 0.165 mmol) in THF (3 mL) was added CDI (107 mg, 0.66 mmol). After 30min, hydrazine (0.1 mL, 1 .65 mmol) was added and stirred for 1 h. The reaction mixture was concentrated under reduced pressure to give the crude product which was purified by column chromatography (silica gel, DCM:MeOH = 10: 1 ) to afford the title compound as a colorless oil (44 mg, 64% yield). LC-MS (ESI): m/z (M+1 ) = 414.4.

Step 2: Ethyl 4,4-dimethyl-2-(5-methyl-2-oxo-4-(5-oxo-4,5-dihydro-1 ,3,4-oxadiazol-2-yl)-6-(p- tolyl)pyridin- 1 (2H)-yl)pentanoate

To a solution of Ethyl 2-(4-(hydrazinecarbonyl)-5-methyl-2-oxo-6-(p-tolyl)pyridin-1 (2/-/)- yl)-4,4-dimethylpentanoate (44 mg, 0.1 1 mmol) and DIPEA (0.04 mL, 0.22 mmol) in DCM (2 mL) was added triphosgene (13 mg, 0.04 mmol). After 30min, the reaction mixture was quenched with water and extracted with DCM (20 ml X 2). The combined organic layers were washed with brine, dried over Na₂S0₄, filtered and concentrated under reduced pressure to give the crude product which was purified by column chromatography (silica gel, PE:EA = 1 :1 ) to afford the title compound as a yellow oil (46 mg, 100% yield). LC-MS (ESI): m/z (M+1 ) = 440.4.

Step 3: Ethvi 4A-dimethvi-2-(5-methvi-4-(5-(((1rAr)-4-methyicvciohexyi)amino)-1,3A-oxa 2-yl)-2-oxo-6-(D-tolyl)Dyridin- 1 (2H)-yl)pentanoate

A mixture of Ethyl 4,4-dimethyl-2-(5-methyl-2-oxo-4-(5-oxo-4,5-dihydro-1 ,3,4-oxadiazol- 2-yl)-6-(p-tolyl)pyridin-1 (2H)-yl)pentanoate (25 mg, 0.06 mmol), (1 Λ,4Λ)-4- methylcyclohexanamine (0.015 mL, 0.1 1 mmol), BOP (28 mg, 0.063 mmol) and DIPEA (0.02 mL, 0.1 1 mmol) in DMF (2 mL) was stirred at ambient temperature for 12h. The reaction mixture was diluted with water and extracted with EtOAc (20 ml X 2). The combined organic layers were washed with brine, dried over Na₂S0₄, filtered and concentrated under reduced pressure to give the crude product which was purified by column chromatography (silica gel, PE:EA = 1 :1 ) to afford the title compound as a yellow oil (20 mg, 66% yield). LC-MS (ESI): m/z (M+1 ) = 535.6.

Step 4: 4A-Di ethyl-2-(5-methyl-4-(5-(((1rAr)-4-methylcvclohexyl)amino)-1 ,3A-oxadiazol-2-vD-

2-oxo-6-(D-tolyl)Dyridin- 1 (2H)-yl)pentanoic acid

To a solution of Ethyl 4,4-dimethyl-2-(5-methyl-4-(5-(((1 r,4r)-4-methylcyclohexyl)amino)- 1 ,3,4-oxadiazol-2-yl)-2-oxo-6-(p-tolyl)pyridin-1 (2H)-yl)pentanoate (20 mg, 0.037 mmol) in MeOH (2 mL) was added 1 N NaOH (0.4 mL) and heated to reflux. After 12h, the reaction mixture was cooled to ambient temperature, acidified with 1 N HCI (0.4 mL) (pH = 6~7) and concentrated under reduced pressure to give the crude product which was purified by reverse phase HPLC (C₁₈60-100% CH₃CN in H₂0 with 0.1% formic acid) to afford the title compound as a white powder (8 mg, 42% yield).¹H NMR (400 MHz, DMSO) δ 12.86 (s, 1H), 7.96 (d, J= 7.5 Hz, 1H), 7.45 - 7.30 (m, 4H), 6.75 (s, 1 H), 4.28 (s, 1 H), 3.39 - 3.36 (m, 1 H), 2.41 (s, 3H), 2.26 - 2.22 (m, 1 H), 2.06 - 1.93 (m, 5H), 1.92 - 1.87 (m, 1 H), 1.75 - 1.68 (m, 2H), 1.37 - 1.27 (m, 3H), 1.08 - 1.01 (m, 2H), 0.89 (d, J= 6.5 Hz, 3H), 0.59 (s, 9H). LC-MS (ESI): m/z (M+1) = 507.6.

The following compounds were prepared in a manner simialar to the procedures described above for examples 1-6.

Example 7: 2-(4-(cvclohexylcarbamoyl)-5-methyl-2-oxo-6-p-tolylpyridin-1 (2H)-yl)-4,4- dimethylpentanoic acid

¹H NMR (400 MHz, DMSO) δ = 12.78 (br, 1H), 8.47 (d, J = 8.0 Hz, 1H), 7.36 (m, 4H), 6.27 (s, 1 H), 4.22 (s, 1 H), 3.71 - 3.63 (m, 1 H), 2.39 (s, 3H), 2.32 - 2.26 (m, 1 H), 1.84 - 1.64 (m, 7H), 1.60- 1.54 (m, 1H), 1.34- 1.06 (m, 6H), 0.58 (s, 9H). LC-MS (ESI): m/z (M+1) = 453.6

Example 8: 2-(4-(cvclohexylmethylcarbamoyl)-5-methyl-2-oxo-6-p-tolylpyridin-1 (2H)-yl)-4,4- dimethylpentanoic acid

¹H NMR (400 MHz, DMSO) δ = 12.92 (br, 1H), 8.57 (t, J = 5.9 Hz, 1H), 7.42-7.28 (m, 4H), 6.29 (s, 1 H), 4.23 (s, 1 H), 3.08 - 3.01 (m, 2H), 2.39 (s,3H), 2.32 - 2.24 (m, 1 H), 1.90 - 1.80 (m, 1H), 1.74- 1.58 (m, 8H), 1.52- 1.44 (m, 1H), 1.24- 1.13 (m, 3H), 0.96 - 0.86 (m, 2H), 0.59 (s, 9H). LC-MS (ESI): m/z (M+1) = 467.6

Example 9: 2-(4-(benzylcarbamoyl)-5-methyl-2-oxo-6-p-tolylpyridin-1 (2H)-yl)-4,4- dimethylpentanoic acid

¹H NMR (400 MHz, DMSO) δ 12.86 (br, 1H), 9.15 (t, J = 5.8 Hz, 1H), 7.67-6.96 (m, 9H), 6.38 (s, 1 H), 4.41 (d, J = 4.7 Hz, 2H), 4.25 (s, 1 H), 2.39 (s, 3H), 2.32 - 2.22 (m, 1 H), 1.92 - 1.78 (m, 1H), 1.67 (s, 3H), 0.59 (s, 9H). LC-MS (ESI): m/z (M+1) = 461.3

Example 10: 2-(3-(cyclohexylmethylsulfonamido^')-5-methyl-2-oxo-6-(p-tolyl^')pyridin-1 (2H)-vD- 4,4-dimethylpentanoic acid

1H NMR (400 MHz, DMSO) δ 12.93 (br, 1H), 8.82 (s, 1H), 7.46-7.25 (m, 5H), 4.31 (s, 1H), 3.05 (d, J = 6.1 Hz, 2H), 2.39 (s, 3H), 2.25-2.19 (m, 1H), 2.04- 1.97 (m, 1H), 1.92- 1.78 (m, 5H), 1.68 - 1.56 (m, 3H), 1.24 - 0.99 (m, 5H), 0.56 (s, 9H). LC-MS (ESI): m/z (M+1) = 503.3

Example 11 : 2-(6-(8-fluoro-5-methylchroman-6-yl)-5-methyl-4-(((1 s,4s)-4- methylcvclohexyl)carbamoyl)-2-oxo ethylpentanoic acid

1H NMR (400 MHz, DMSO) δ 8.45 (d, J = 8.1 Hz, 1 H), 7.03 - 6.84 (m, 1H), 6.23 (s, 1H), 4.23- 4.15 (m, 3H), 3.61 - 3.55 (m, 1 H), 2.72 - 2.56 (m, 2H), 2.42 - 2.32 (m, 1 H), 2.05 - 1.88 (m, 5H), 1.85- 1.75 (m, 2H), 1.71 - 1.62 (m,2H), 1.55 (d, J = 24.2 Hz, 3H), 1.33-1.16 (m, 4H), 1.03- 0.91 (m, 2H), 0.85 (d, J = 6.5 Hz, 3H), 0.61 (d, J = 33.7 Hz, 9H). LC-MS (ESI): m/z (M+1) =

541.9

Biological Examples ANTI-HIV ACTIVITY

MT4 Assay

Antiviral HIV activity and cytotoxicity values for compounds of the invention from Table 1 were measured in parallel in the HTLV-1 transformed cell line MT-4 based on the method previously described (Hazen et al., 2007, In vitro antiviral activity of the novel, tyrosyl-based human immunodeficiency virus (HIV) type 1 protease inhibitor brecanavir (GW640385) in combination with other antiretrovirals and against a panel of protease inhibitor-resistant HIV (Hazen et al., "In vitro antiviral activity of the novel, tyrosyl-based human immunodeficiency virus (HIV) type 1 protease inhibitor brecanavir (GW640385) in combination with other antiretrovirals and against a panel of protease inhibitor-resistant HIV", Antimicrob. Agents Chemother. 2007, 51 : 3147-3154; and Pauwels et al., "Sensitive and rapid assay on MT-4 cells for the detection of antiviral compounds against the AIDS virus", J. of Virological Methods 1987, 16: 171-185).

Luciferase activity was measured 96 hours later by adding a cell titer glo (Promega, Madison, Wis.). Percent inhibition of cell protection data was plotted relative to no compound control. Under the same condition, cytotoxicity of the compounds was determined using cell titer Glo™ (Promega, Madison, Wis). IC₅₀s were determined from a 10 point dose response curve using 3-4-fold serial dilution for each compound, which spans a concentration range > 1000 fold.

These values are plotted against the molar compound concentrations using the standard four parameter logistic equation: y = ((Vmax ^* χ^Λη) / (Κ^Λη + χ^Λη)) + Y2

where:

Y2 = minimum y n = slope factor

Vmax= maximum y x = compound concentration [M]

When tested in the MT4 assay compounds were found to have IC₅₀ values listed in Table 2. Table 2

Claims

What is claimed is:

1. A compound of Formula I:

Formula I

wherein:

2. A compound according to Claim 1 wherein R¹ is phenyl optionally substituted by a methyl group.

3. A compound according to Claim 1 or 2 wherein L is a bond, -oxadiazolyl-NH-, -C(0)NH-, or - C(0)NHCH₂-.

4. A compound according to any of Claims 1 -3 wherein R² is H, cyclohexyl, or phenyl wherein said cyclohexyl and phenyl are optionally substituted by 1 or 2 methyl groups.

5. A compound according to any of Claims 1 -4 wherein R³ is H, -NHS0₂CH₃, or - NHS0₂CH₂cyclohexyl.

6. A compound according to any of Claim 1 -5 wherein the stereochemistry on the carbon to which the t-butyl group is bound is as depicted below.

7. A pharmaceutically acceptable salt of a compound according to any of Claims 1 -6.

8. A pharmaceutical composition comprising a compound or salt according to any of Claims 1 - 7.

9. A method for treating a viral infection in a patient mediated at least in part by a virus in the retrovirus family of viruses, comprising administering to said patient a composition according to Claim 8.

10. The method of Claim 9 wherein said viral infection is mediated by the HIV virus.

1 1 . A compound or salt as defined in any of Claims 1 -7 for use in medical therapy.

12. A compound or salt as defined in any of Claims 1 -7 for use in the treatment of a viral infection in a human.

13. The use of a compound or salt as defined in any of Claims 1 -7 In the manufacture of a medicament for use in the treatment of a viral infection in a human.